Raedler, L. A. (2016). Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma. Am Health Drug Benefits.
استشهاد بنمط شيكاغوRaedler, Lisa A. "Revlimid (Lenalidomide) Now FDA Approved As First-Line Therapy for Patients With Multiple Myeloma." Am Health Drug Benefits 2016.
MLA استشهادRaedler, Lisa A. "Revlimid (Lenalidomide) Now FDA Approved As First-Line Therapy for Patients With Multiple Myeloma." Am Health Drug Benefits 2016.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.